ライフサイエンスコーパス: double-blind study

1 pen appendectomy in a prospective randomized double blind study.

2 lacebo with MTX (placebo group), in a 2-year double-blind study.

3 perphenazine, with several newer drugs in a double-blind study.

4 d to receive colchicine or methotrexate in a double-blind study.

5 , 10 to 28 mm) in a prospective, randomized, double-blind study.

6 This was a multicenter, randomized, double-blind study.

7 e enrolled in this prospective, multicentre, double-blind study.

8 fter one month off of hormone treatment in a double-blind study.

9 nate therapy after 1 month off therapy, in a double-blind study.

10 this prospectively in a larger, randomized, double-blind study.

11 cirrhosis were included in this prospective, double-blind study.

12 e mania who entered a 3-week parallel group, double-blind study.

13 nts) once daily at bedtime for 12 weeks in a double-blind study.

14 nrolled in a randomized, placebo-controlled, double-blind study.

15 es daily (n=83) for 5 days in a multicenter, double-blind study.

16 R) was recently established in a prospective double-blind study.

17 enrolled in this randomized parallel group, double-blind study.

18 alone to the other nostril in a randomized, double-blind study.

19 IVIg or placebo, monthly, for 3 months in a double-blind study.

20 lovir (ganciclovir group) until day 100 in a double-blind study.

21 placebo (n=83) for 24 weeks in a randomized, double-blind study.

22 studied in a placebo-controlled, randomized, double-blind study.

23 n a phase 2, randomized, placebo-controlled, double-blind study.

24 r placebo (n=15) for 14 days in a randomized double-blind study.

25 stage IV metastasis tissue microarrays in a double-blind study.

26 ncer positive and negative samples through a double-blind study.

27 ion in Alsace) is a prospective, randomized, double-blind study.

28 model of acute inflammation) or placebo in a double-blind study.

29 1) for 12 months in a phase II, multicentre, double-blind study.

30 e 2.5 mg daily or tamoxifen 20 mg daily in a double-blinded study.

31 Randomized, placebo-controlled, double-blinded study.

32 t cancer were randomized to two multicenter, double-blind studies (088001 and 088006).

33 Of 3,964 patients in double-blind studies, 1,427 had a history of atrial fibr

34 In this 24-week multicenter, randomized, double-blind study, 1,220 type IIa or IIb hyperlipidemic

35 METHODS AND In a multicenter, randomized, double-blind study, 123 patients with stable coronary ar

36 In this phase 2, double-blind study, 124 subjects with biopsy-proven NASH

37 In this double-blind study, 127 patients with psoriatic arthriti

38 In a double-blind study, 148 clinically stable, overweight (b

39 In a randomized, double-blind study, 17 healthy human subjects received o

40 In this double-blind study, 17 HIV-infected individuals with vir

41 In a parallel-group, double-blind study, 179 patients hospitalized for acute

42 In this double-blind study, 1797 patients with hypertension (mea

43 In the double-blind study, 20 of the 29 patients in the recombi

44 In the double-blind study, 21 of the 26 patients who received p

45 , randomized, flexible-dose, parallel-group, double-blind study, 280 men with erectile dysfunction fo

46 In this randomized double-blind study, 399 students either wrote about thei

47 In this 4-week double-blind study, 404 patients were randomized to 20 m

48 In this double-blind study, 420 postmenopausal women were random

49 In this randomized double-blind study, 43 HIV-1-infected patients received

50 In a parallel-group, double-blind study, 52 (14 men, 38 women) healthy normal

51 In this multicenter, double-blind study, 615 patients with first-ever unprovo

52 In a double-blind study, 628 patients with baseline LDL-C 145

53 In this 24-week, double-blind study, 672 patients underwent randomization

54 receive fluoxetine or placebo in a 12-week, double-blind study; 73% (59 of 81) of the patients in ea

55 In a double-blind study, 80 depressed patients were randomize

56 In this double-blind study, 87 immunocompromised patients with c

57 In this double-blind study, 97 HIV-infected patients who had rec

58 In this double-blind study, adult patients with hyperuricemia an

59 In a multicenter, double-blind study, adults (ages 18-64 years) with treat

60 In this randomized, double-blind study, adults with HDM-associated allergic

61 In a 3 d double-blind study and in a 10 d repeated stimulation st

62 se who responded to treatment then entered a double-blind study and were randomly assigned to receive

63 patients who were enrolled, 400 entered the double-blind study, and 370 received at least one postba

64 A randomized, double-blind study assessed the efficacy and safety of p

65 plus anakinra (100 mg/day) for 6 months in a double-blind study at 41 centers in the US.

66 We performed a double-blind study at 49 hospitals in Europe and Israel,

67 We performed a prospective, randomized, double-blind study at 5 level 1 trauma centers.

68 This 12-month double-blind study attempted remission induction using s

69 In this double-blind study children with PA were randomized to r

70 In a double-blind study, children and adolescents with ADHD (

71 For patients who completed the 10-week double-blind study, clozapine was superior to haloperido

72 This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5

73 This multicenter, randomized, double-blind study compared mibefradil with placebo as a

74 This randomized, double-blind study compared olanzapine, quetiapine, risp

75 This double-blind study compared the effect of palifermin wit

76 This multicenter, randomized, double-blind study compared the efficacy and safety of i

77 This randomized double-blind study compared the efficacy and safety of i

78 andomized, placebo-controlled, double-dummy, double-blind study compared the magnitude and duration o

79 A randomized double-blind study comparing aprepitant versus dexametha

80 3 patients were enrolled in this randomized, double-blind study comparing losartan (50 to 100 mg once

81 mary sclerosing cholangitis in a randomized, double-blind study comparing ursodiol (13 to 15 mg per k

82 A 6-week, randomized, double-blind study conducted between February 2013 and M

83 X-ACT was a phase III, randomized, double-blind study conducted in 24 centres (Germany), wh

84 NG, AND PATIENTS: Single-center, randomized, double-blind study conducted in a level 3 pediatric inte

85 In a double-blind study conducted in the winter, 30 healthy m

86 scertainment bias, and only 2 studies with a double-blinded study design have been conducted.

87 hat involves randomized, placebo-controlled, double-blind studies designed to maximize statistical po

88 In a double-blind study, desipramine or placebo was added for

89 In this randomised, double-blind study, done at 87 sites in 13 countries, we

90 ent groups who received at least one dose of double-blind study drug.

91 After participating in a 12-week multicenter double-blind study during which they received placebo or

92 In this randomised, double-blind study eligible patients were aged 36-70 yea

93 In this phase 3 double-blind study, eligible participants were children

94 The primary double-blind study end points were changes between basel

95 multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of

96 This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of

97 This double-blind study evaluated treatment with either a sin

98 iomarkers, a placebo controlled, randomized, double blinded study in active steroid dependent and ste

99 We conducted separate randomized, double-blind studies in 38 centers in North America and

100 We conducted a multicenter, randomized, double-blind study in 394 healthy adults.

101 f this prospective, multicenter, randomized, double-blind study in cardiac transplant patients were:

102 We conducted a prospective, randomized, double-blind study in healthy, preterm infants (gestatio

103 c Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic

104 ulticenter, prospective, placebo-controlled, double-blind study in which 564 high-risk patients under

105 We conducted a randomized, double-blind study in which 87 patients between 8 and 40

106 This study was conducted as a double-blind study in which eight groups of middle-aged

107 We conducted a double-blind study in which previously untreated adults

108 t the results of a multinational randomized, double-blind study, in which postmenopausal women with o

109 AMBITION was a multicentre, randomised, double-blind study, in which treatment-naive patients wi

110 This prospective, multicenter, randomized, double-blind study included 397 patients who were random

111 In randomized, double-blind studies, infiltration of the neurovascular

112 In a 6-week double-blind study, inpatients with a recent exacerbatio

113 ER PFO Occluder to Medical Management) was a double-blind study investigating migraine characteristic

114 This was a double-blind study investigating the effects of three do

115 This randomized, double-blind study involved three antiretroviral regimen

116 In this randomized, double-blind study involving 10 days of treatment and 30

117 In this double-blind study involving 142 patients with metastati

118 d an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing

119 population studies [PS]) were evaluated in a double-blind study involving 284 methicillin-resistant S

120 ed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low lev

121 ingle-blind placebo on day -1 (baseline) and double-blind study medication (placebo [n = 12] or lixiv

122 d patients who received at least one dose of double-blind study medication and who had both a baselin

123 In 2 phase III, randomized, double-blind studies, men and women with HIV-associated

124 In a randomized double-blind study (n = 127), science faculty from resea

125 In the double-blind study, none of the 12 lesions in the six pa

126 alth Initiative study in 2002, a prospective double-blind study, noted an increased risk of breast ca

127 In a double-blind study, nucleos(t)ide-naive patients with hi

128 il, administered as needed in two sequential double-blind studies of men with erectile dysfunction of

129 atic review and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy

130 randomized, prospective, placebo-controlled, double-blind study of 122 patients at 17 centers in Euro

131 In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine rec

132 We performed a double-blind study of 165 patients with primary biliary

133 In a double-blind study of 40 patients with malignant melanom

134 multicenter, randomized, placebo-controlled, double-blind study of 58 patients who were treated every

135 A double-blind study of 672 patients with OA of the knee w

136 COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5

137 e then performed a randomized placebo-phase, double-blind study of alirocumab 150 mg administered sub

138 lled in this randomized, placebo-controlled, double-blind study of AZ 100 mg on all-cause mortality.

139 lled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mort

140 conducted a randomized, placebo-controlled, double-blind study of clarithromycin in patients with AI

141 ors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meetin

142 ACh response was determined in a randomized double-blind study of eight healthy subjects, who were s

143 of <1 year's duration had been enrolled in a double-blind study of minocycline (100 mg twice daily) v

144 Data were obtained from a randomized, double-blind study of patients with moderate-to-severe f

145 Randomized, double-blind study of patients with schizophrenia assign

146 in Intolerant Subjects) trial was a 12-week, double-blind study of randomized patients (2:2:1:1) to e

147 ts (n = 105) were enrolled into a randomized double-blind study of rimantadine treatment of experimen

148 ffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and halop

149 acebo-controlled, dose-response, randomized, double-blind study of the effect of vitamin D on calcium

150 A randomized, double-blind study of valaciclovir for suppression of re

151 Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used a

152 00 cases) that participated in a randomized, double-blinded study of intracoronary RT completed a que

153 In a Phase II double-blind study, orally administered interferon alpha

154 lysis of a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years w

155 In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any su

156 In a double-blind study, patients received placebo or a probi

157 In this double-blind study, patients with DSM-IV generalized anx

158 In this multicenter, investigator-initiated, double-blind study, patients with first-ever unprovoked

159 In this double-blind study, patients with type 2 diabetes (eithe

160 This 6-month, double-blind study randomized patients with moderate to

161 This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorde

162 Recent large randomized double-blind studies show the efficacy of these agents i

163 In a randomized, double-blind study, sildenafil 100 mg or placebo was giv

164 In two identical phase 3, double-blind studies (study 04, 652 participants; study

165 In this multicenter, double-blind study, symptomatic HIV-infected children 3

166 This randomized, double-blind study tested the hypothesis that rofecoxib,

167 onary artery lesions) trial is a randomized, double-blind study that compared sirolimus-eluting and b

168 tients were part of the URICO-ICTUS trial, a double-blind study that compared the administration of u

169 Phase 2 was a double-blind study that randomly assigned patients (1:1:

170 In this 8-wk double-blind study the hemodialysis patients were random

171 In a placebo-controlled, double-blind study, the authors investigated the efficac

172 In a randomized, double-blind study, the efficacy of scorpion-specific F(

173 In the double-blind study, there were no significant difference

174 conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-t

175 We performed a prospective, randomized, double-blind study to determine whether calcium and calc

176 (mean age, 70.7 years) were randomized in a double-blind study to either active estrogen patch or id

177 We performed a crossover, randomized, double-blind study to evaluate HT bioavailability in HT-

178 Fontan procedure, we performed a randomized, double-blind study to evaluate the impact of an incision

179 ate to severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/flu

180 real circulation were randomly assigned in a double-blind study to receive high-dose aprotinin, epsil

181 mbricoides-infected subjects randomized in a double-blind study to receive two doses of either albend

182 A randomized double-blinded study to define the activity of IM862 in

183 We undertook a double-blind study using stereological cell counting met

184 Here, in a double-blinded study using objective spatiotemporal gait

185 and of sulindac, as a positive control, in a double-blind study, using azoxymethane-induced colonic a

186 ating esophageal candidiasis was tested in a double-blind study versus oral fluconazole.

187 S: A prospective, single-center, randomized, double-blind study was conducted at the Brazilian Center

188 A phase III, randomized, double-blind study was conducted by the North Central Ca

189 This randomized, double-blind study was conducted in 142 sites in 17 coun

190 A randomized, placebo-controlled, double-blind study was conducted in healthy adults aged

191 A randomized, crossover, double-blind study was conducted in healthy and MetS adu

192 A randomized, double-blind study was conducted to assess the anti-HIV

193 A multicenter, double-blind study was conducted to determine rates of s

194 A randomized, double-blind study was conducted to evaluate the pharmac

195 An 8-week double-blind study was conducted with 28 patients who we

196 This double-blind study was designed to assess the effects of

197 A 12-week, randomized, double-blind study was designed to compare gabapentin (1

198 ndomized, parallel-group, placebo-controlled double-blind study was performed at university and commu

199 A prospective double-blind study was performed comparing VHC to vancom

200 The aim of this prospective randomized double-blind study was to compare the efficacy and safet

201 The purpose of this double-blind study was to evaluate the efficacy of the L

202 This randomised, double-blind study was undertaken in 117 sites in North

203 A multicenter, randomized, double-blind study was undertaken in 2342 infants to eva

204 prospective, randomized, placebo-controlled, double-blinded study was performed in 6 academic medical

205 Recently, a prospective, double-blinded study was performed to help settle the de

206 In a multicenter randomized double-blind study we demonstrated that Qiliqiangxin (QL

207 In a cross-sectional, placebo-controlled, double-blind study we examined the effect of 10-12 y of

208 In two multisite, randomized, double-blind studies, we compared a single application o

209 In four multicenter, randomized, double-blind studies, we randomly assigned patients with

210 multicenter, randomized, placebo-controlled, double-blind study, we assign 597 subjects with psoriasi

211 In this randomized, double-blind study, we assigned 14,671 patients to add e

212 In this randomized, double-blind study, we compared apixaban (at a dose of 1

213 In a randomized, double-blind study, we compared lorazepam with placebo f

214 In this randomized, double-blind study, we compared the effect of 6 months o

215 In this randomized, double-blind study, we compared two doses of apixaban (2

216 In this randomised, placebo-controlled, double-blind study, we enrolled adults (aged 18-80 years

217 In this randomised, placebo-controlled, double-blind study, we enrolled patients aged 18 years o

218 multicenter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatmen

219 In a double-blind study, we evaluated subjects with the amnes

220 In this phase 3, multicenter, randomized, double-blind study, we evaluated the efficacy and safety

221 In a double-blind study, we randomly assigned 1049 consecutiv

222 In this double-blind study, we randomly assigned 1088 patients t

223 In this double-blind study, we randomly assigned 2392 young wome

224 In a multicenter, double-blind study, we randomly assigned 255 patients wi

225 In a placebo-controlled, double-blind study, we randomly assigned 32 healthy volu

226 In this phase 3, double-blind study, we randomly assigned 443 patients wi

227 In a substudy of a larger double-blind study, we randomly assigned 602 healthy men

228 the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1

229 In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 rat

230 Patients who completed the double-blind study were then entered into a 1-year open-

231 Double-blind studies with sufficient power to resolve th

232 l 2 x 2 x 2, randomized, placebo-controlled, double-blind study with 3 active treatments: folic acid

233 In this double-blind study with a 2-by-2 factorial design, we ra

234 rative Study was a prospective, multicenter, double-blind study with consecutive enrollment of patien

235 A prospective double-blinded study with preset sonographic criteria ha

236 Drug-Eluting Stent Below the Knee-Randomised Double-Blind Study [YUKON-BTX]; NCT00664963).